Recently,The 8th iSEE Global AwardsAward Ceremony Successfully Held, Xbiome Wins Two Major Awards:Xbiome's "China-produced Strain" XA-1416 for Weight Management and Fat Reduction Shortlisted in iSEE Top 100 Innovative Technologies; Its Consumer Probiotics Brand Youngluck's "Ready-to-eat Probiotics" Product Wins iSEE Top 100 Innovative Brands.The "double success" in both strain and product dimensions demonstrates Xbiome's innovative strength and industry influence in the field of gut microbiota.
The iSEE Innovation Award, initiated by Foodaily, a renowned media in the food industry, focuses on global food innovation from a business ecosystem perspective. It pioneered six evaluation dimensions, including product innovation, consumer insight, user experience, consumer value, commercial performance, and technology leadership, and is acclaimed as..."Innovation Trendsetter in the Food Industry", as the authoritative benchmark for measuring food innovation. This year's selection attracted 5,688 cases from multiple countries and regions, including China, Japan, South Korea, Europe, North America, and Australia/New Zealand. Xbiome ultimately stood out among numerous participants by showcasing its AI+BT capabilities in the development of XA-1416, along with the scientific branding power of its product Yang Le Jun.
XA-1416: Lightweight Fat Reduction "China Bacteria"
Obesity has become a major global health challenge. In June 2024, the National Health Commission and 15 other departments in China officially launched a three-year special campaign called "Weight Management Year," elevating the resolution of obesity issues to a national strategy. Managing health through gut microbiota is one of the current research hotspots in academia. Numerous studies have strongly confirmed that probiotics are highly effective in weight management.
Salivary Lactobacillus XA-1416It is a patented functional strain independently developed by Xbiome, derived from the intestines of healthy Chinese adults. According to patent information, its main function is fat reduction and weight loss, creating an easy-to-lose-weight physique. Through a series of animal and human clinical trials, XA-1416 has shown excellent results in weight management.
XA-1416 Under the Microscope
Xbiome's scientific team's research results show that XA-1416 hasRegulate the ratio of obesity-prone/lean-prone bacteria, promote cholesterol decomposition and excretion, inhibit adipocyte accumulation and differentiation, and increase GLP-1 and PP hormone levels.Through various scientific mechanisms, it achieves effortless fat reduction and weight loss without changing dietary or exercise habits, perfectly aligning with the contemporary young population's health demands for "efficient, low-burden weight loss."
Currently, XA-1416 has been granted a national patent authorization. Xbiome has achieved the commercialization of XA-1416 through methods such as strain licensing and OEM, completing the closed loop of "technological innovation-industrial transformation-market implementation," providing the industry with a replicable model for the commercialization of Chinese-produced strains. Companies that are clients for XA-1416 include well-known food and probiotic brands in China such as Chayan Yuese and Health Express.
Yangle Jun Ready-to-Eat Probiotics: Setting a Scientific Probiotic Benchmark
Yangle Jun's "Ready-to-Eat Probiotics" Won iSEE Innovation Brand Top 100. The main advantage of the product lies in its core of star patented strains such as Xbiome XA-1416, practicing the brand concept of "scientific evidence and precise matching." Different from the traditional probiotics brands' model of "heavy marketing, light research," Yangle Jun relies on Xbiome's strong R&D strength to precisely meet the gut health needs of different populations according to the principles of precision effectiveness, scientific quantification, and transparent pathways, improving the gut microbiota of Chinese people. With the reputation of being "professional and reliable," Yangle Jun has become the benchmark for scientific probiotics in consumers' minds.
This double award win not only represents the iSEE Innovation Award's high recognition of Xbiome’s "strain innovation + product focus" dual-driven approach in probiotic research, but also serves as a strong testament to the rapid rise of China-based probiotic companies. Adhering to the principle of "serving the Chinese people with Chinese bacteria," Xbiome leverages the integration of AI and biotechnology to break the foreign monopoly on probiotic strain technology, enabling the swift implementation of self-developed functional strains in China. By addressing critical public health challenges, Xbiome provides new pathways for innovation in the food and broader health industries.
Xbiome will continue to leverage its AI microbiome R&D platform to bring more "China-produced bacteria" to the market. By researching and designing better probiotic products, it aims to help consumers rebuild their gut microbiota for a healthier life, making high-quality probiotics accessible to a wider consumer base. Through technological innovation, Xbiome is committed to advancing the "Healthy China 2030" strategy.
-End-